MA52411B1 - Dérivés de 2,4-diaminoquinazoline et leurs utilisations dans le traitement des infections virales, cancer et des allergies - Google Patents
Dérivés de 2,4-diaminoquinazoline et leurs utilisations dans le traitement des infections virales, cancer et des allergiesInfo
- Publication number
- MA52411B1 MA52411B1 MA52411A MA52411A MA52411B1 MA 52411 B1 MA52411 B1 MA 52411B1 MA 52411 A MA52411 A MA 52411A MA 52411 A MA52411 A MA 52411A MA 52411 B1 MA52411 B1 MA 52411B1
- Authority
- MA
- Morocco
- Prior art keywords
- fluorine
- methyl
- deuterium
- cyclopropyl
- formula
- Prior art date
Links
- 206010020751 Hypersensitivity Diseases 0.000 title abstract 2
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 208000036142 Viral infection Diseases 0.000 title abstract 2
- 230000007815 allergy Effects 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title abstract 2
- 230000009385 viral infection Effects 0.000 title abstract 2
- XELRMPRLCPFTBH-UHFFFAOYSA-N quinazoline-2,4-diamine Chemical class C1=CC=CC2=NC(N)=NC(N)=C21 XELRMPRLCPFTBH-UHFFFAOYSA-N 0.000 title 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 abstract 6
- 229910052731 fluorine Inorganic materials 0.000 abstract 6
- 239000011737 fluorine Substances 0.000 abstract 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 6
- 229910052739 hydrogen Inorganic materials 0.000 abstract 5
- 239000001257 hydrogen Substances 0.000 abstract 5
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical group [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 abstract 4
- 229910052805 deuterium Inorganic materials 0.000 abstract 4
- 150000001408 amides Chemical class 0.000 abstract 3
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 abstract 3
- 150000002431 hydrogen Chemical group 0.000 abstract 3
- 150000002825 nitriles Chemical class 0.000 abstract 3
- 125000001424 substituent group Chemical group 0.000 abstract 3
- 125000006163 5-membered heteroaryl group Chemical group 0.000 abstract 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical group [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 abstract 2
- 239000000460 chlorine Chemical group 0.000 abstract 2
- 229910052801 chlorine Inorganic materials 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000000623 heterocyclic group Chemical group 0.000 abstract 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 abstract 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 241000700605 Viruses Species 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 208000026935 allergic disease Diseases 0.000 abstract 1
- 125000003277 amino group Chemical group 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 150000001733 carboxylic acid esters Chemical group 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- -1 methoxy, cyclopropyl Chemical group 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 abstract 1
- 150000003246 quinazolines Chemical class 0.000 abstract 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
La présente invention concerne des dérivés de quinazoline de formule (i), des compositions pharmaceutiques comprenant les composés de formule (i), et l'utilisation des composés de formule (i) dans le traitement ou la prévention d'une infection virale, d'une maladie induite par un virus, du cancer ou d'une allergie. Dans la formule (i), r1 représente un alkyle en c3-8, éventuellement substitué par un ou plusieurs substituants choisis indépendamment parmi le fluor, hydroxyle, amino, nitrile, ester, amide, alkyle en c1-3, ou alcoxy en c1-3, le carbone de r1 lié à l'amine en position 4 de la quinazoline est dans la configuration (r), r2 représente l'hydrogène, deutérium, fluor, chlore, méthyle, méthoxy, cyclopropyle, trifluorométhyle, ou amide carboxylique, chacun parmi le méthyle, méthoxy et cyclopropyle étant éventuellement substitué par un ou plusieurs substituants indépendamment choisis parmi le fluor et le nitrile, r3 représente l'hydrogène ou le deutérium, r4 représente l'hydrogène, deutérium, fluor, méthyle, ester carboxylique, amide carboxylique, nitrile, cyclopropyle, hétérocycle en c4-7, ou un groupe hétéroaryle à 5 chaînons, chacun des groupes méthyle, cyclopropyle, hétérocycle en c4-7 et hétéroaryle à 5 chaînons étant éventuellement substitué par un ou plusieurs substituants indépendamment choisis parmi le fluor, hydroxyle, ou méthyle, r5 représente un atome d'hydrogène, de deutérium, de fluor, de chlore, de méthyle ou de méthoxy, à condition qu'au moins l'un de r2, r3, r4 et r5 ne représentent pas de l'hydrogène.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18159583 | 2018-03-01 | ||
| PCT/EP2019/054941 WO2019166532A1 (fr) | 2018-03-01 | 2019-02-28 | Dérivés de 2,4-diaminoquinazoline et leurs utilisations médicales |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA52411A MA52411A (fr) | 2021-01-06 |
| MA52411B1 true MA52411B1 (fr) | 2022-12-30 |
Family
ID=61557126
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA52411A MA52411B1 (fr) | 2018-03-01 | 2019-02-28 | Dérivés de 2,4-diaminoquinazoline et leurs utilisations dans le traitement des infections virales, cancer et des allergies |
Country Status (32)
| Country | Link |
|---|---|
| US (2) | US11597704B2 (fr) |
| EP (2) | EP4059924A1 (fr) |
| JP (1) | JP2021514981A (fr) |
| KR (1) | KR20200128394A (fr) |
| CN (1) | CN111868040A (fr) |
| AR (1) | AR114420A1 (fr) |
| AU (1) | AU2019226342B2 (fr) |
| BR (1) | BR112020017702A2 (fr) |
| CA (1) | CA3091076A1 (fr) |
| CL (3) | CL2020002253A1 (fr) |
| CY (1) | CY1125489T1 (fr) |
| DK (1) | DK3759083T3 (fr) |
| EA (1) | EA202092052A1 (fr) |
| ES (1) | ES2923579T3 (fr) |
| HR (1) | HRP20220781T1 (fr) |
| HU (1) | HUE059149T2 (fr) |
| IL (2) | IL276952B2 (fr) |
| JO (2) | JOP20200208B1 (fr) |
| LT (1) | LT3759083T (fr) |
| MA (1) | MA52411B1 (fr) |
| MD (1) | MD3759083T2 (fr) |
| MX (2) | MX2020009071A (fr) |
| PH (1) | PH12020551345A1 (fr) |
| PL (1) | PL3759083T3 (fr) |
| PT (1) | PT3759083T (fr) |
| RS (1) | RS63401B1 (fr) |
| SG (1) | SG11202008293YA (fr) |
| SI (1) | SI3759083T1 (fr) |
| SM (1) | SMT202200315T1 (fr) |
| TW (2) | TW202415645A (fr) |
| UA (1) | UA127590C2 (fr) |
| WO (1) | WO2019166532A1 (fr) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20180038465A (ko) | 2015-08-07 | 2018-04-16 | 애로우헤드 파마슈티컬스 인코포레이티드 | Ｂ형 간염 바이러스 감염에 대한 ｒｎａｉ 치료법 |
| JOP20190015A1 (ar) | 2016-08-04 | 2019-02-04 | Arrowhead Pharmaceuticals Inc | عوامل (ار ان ايه آي) لعدوى فيروس الالتهاب الكبدي الوبائي ب |
| TW202415645A (zh) * | 2018-03-01 | 2024-04-16 | 愛爾蘭商健生科學愛爾蘭無限公司 | ２，４－二胺基喹唑啉衍生物及其醫學用途 |
| US12187706B2 (en) * | 2019-01-14 | 2025-01-07 | Innate Tumor Immunity, Inc. | NLRP3 modulators |
| US20220241402A1 (en) * | 2019-06-18 | 2022-08-04 | Janssen Sciences Ireland Unlimited Company | Combination of hepatitis b virus (hbv) vaccines and quinazoline derivatives |
| CN112390795A (zh) * | 2019-08-19 | 2021-02-23 | 上海挚盟医药科技有限公司 | 一类2-氨基嘧啶类化合物及其药物组合物和用途 |
| CN114555565B (zh) * | 2019-12-13 | 2024-03-05 | 四川科伦博泰生物医药股份有限公司 | 含氮并环化合物、其制备方法及用途 |
| KR20220123437A (ko) * | 2020-01-02 | 2022-09-06 | 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 | 피리도피리미딘 유도체의 결정형 및 이의 제조 방법 |
Family Cites Families (100)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3012964A (en) | 1958-06-24 | 1961-12-12 | Universal Oil Prod Co | Hydrocarbon oil composition |
| US3022077A (en) | 1958-09-15 | 1962-02-20 | Doonan William | Arrowhead construction |
| JP2610889B2 (ja) | 1987-09-03 | 1997-05-14 | 日本臓器製薬株式会社 | 新規架橋アデニン誘導体 |
| TW552261B (en) | 1996-07-03 | 2003-09-11 | Japan Energy Corp | Novel purine derivative |
| TR199900389T2 (xx) | 1996-08-28 | 2000-06-21 | Pfizer Inc. | �kame edilmi� 6,5-hetero-bisiklik t�revleri. |
| CA2267103C (fr) | 1996-10-04 | 2006-05-30 | Kyorin Pharmaceutical Co., Ltd. | Derives de pyrazolopyridylpyridazinone et procede de preparation des ces derniers |
| AR012634A1 (es) | 1997-05-02 | 2000-11-08 | Sugen Inc | Compuesto basado en quinazolina, composicion famaceutica que lo comprende, metodo para sintetizarlo, su uso, metodos de modulacion de la funcion deserina/treonina proteinaquinasa con dicho compuesto y metodo in vitro para identificar compuestos que modulan dicha funcion |
| US6339089B2 (en) | 1997-08-13 | 2002-01-15 | Fujirebio Inc. | Pyrimidine nucleus-containing compound and a medicament containing the same for a blood oxygen partial pressure amelioration, and a method for preparing the same |
| CA2311742C (fr) | 1997-11-28 | 2009-06-16 | Sumitomo Pharmaceuticals Co., Ltd. | Nouveaux composes heterocycliques |
| TW572758B (en) | 1997-12-22 | 2004-01-21 | Sumitomo Pharma | Type 2 helper T cell-selective immune response inhibitors comprising purine derivatives |
| US6187777B1 (en) | 1998-02-06 | 2001-02-13 | Amgen Inc. | Compounds and methods which modulate feeding behavior and related diseases |
| JP2002503662A (ja) | 1998-02-17 | 2002-02-05 | テュラリク インコーポレイテッド | 抗ウイルス性ピリミジン誘導体 |
| US6110929A (en) | 1998-07-28 | 2000-08-29 | 3M Innovative Properties Company | Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof |
| JP4342007B2 (ja) | 1998-08-10 | 2009-10-14 | 大日本住友製薬株式会社 | キナゾリン誘導体 |
| JP4315300B2 (ja) | 1998-08-10 | 2009-08-19 | 大日本住友製薬株式会社 | 新規なキナゾリン誘導体 |
| WO2000012487A1 (fr) | 1998-08-27 | 2000-03-09 | Sumitomo Pharmaceuticals Co., Ltd. | Derives de pyrimidine |
| US6583148B1 (en) | 1999-04-08 | 2003-06-24 | Krenitsky Pharmaceuticals, Inc. | Neurotrophic substituted pyrimidines |
| US6503908B1 (en) | 1999-10-11 | 2003-01-07 | Pfizer Inc | Pharmaceutically active compounds |
| WO2002088079A2 (fr) | 2001-05-01 | 2002-11-07 | Bristol-Myers Squibb Company | Inhibiteurs doubles de pde 7 et pde 4 |
| WO2003055890A1 (fr) | 2001-12-21 | 2003-07-10 | Bayer Pharmaceuticals Corporation | Composes derives de thienopyrimidine utilises comme inhibiteurs de la prolylpeptidase, inducteurs d'apoptose et agents de traitement anticancereux |
| US7091232B2 (en) | 2002-05-21 | 2006-08-15 | Allergan, Inc. | 4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones and 4-(substituted cycloalkenylmethyl) imidazol-2-ones and related compounds |
| TW200407143A (en) | 2002-05-21 | 2004-05-16 | Bristol Myers Squibb Co | Pyrrolotriazinone compounds and their use to treat diseases |
| AU2003242252A1 (en) | 2002-06-07 | 2003-12-22 | Kyowa Hakko Kogyo Co., Ltd. | Bicyclic pyrimidine derivatives |
| KR101111085B1 (ko) | 2002-09-27 | 2012-04-12 | 다이닛본 스미토모 세이야꾸 가부시끼가이샤 | 신규 아데닌 화합물 및 그 용도 |
| US8455458B2 (en) | 2002-10-16 | 2013-06-04 | Arthrodynamic Technologies, Animal Health Division, Inc. | Composition and method for treating connective tissue damage |
| JP2007524615A (ja) | 2003-06-20 | 2007-08-30 | コーリー ファーマシューティカル ゲーエムベーハー | 低分子トール様レセプター（ｔｌｒ）アンタゴニスト |
| ATE465742T1 (de) | 2003-09-05 | 2010-05-15 | Anadys Pharmaceuticals Inc | Tlr7-liganden zur behandlung von hepatitis c |
| EP1728792A4 (fr) | 2004-03-26 | 2010-12-15 | Dainippon Sumitomo Pharma Co | Compose 8-oxoadenine |
| US8012964B2 (en) | 2004-03-26 | 2011-09-06 | Dainippon Sumitomo Pharma Co., Ltd. | 9-substituted 8-oxoadenine compound |
| WO2007084413A2 (fr) | 2004-07-14 | 2007-07-26 | Ptc Therapeutics, Inc. | Procedes de traitement de l’hepatite c |
| RU2401833C2 (ru) | 2004-08-10 | 2010-10-20 | Янссен Фармацевтика Н.В. | Производные 1, 2, 4-триазин-6-она, ингибирующие вич |
| JP2008519083A (ja) | 2004-11-09 | 2008-06-05 | エフ．ホフマン−ラ ロシュ アーゲー | アミノキナゾリン化合物 |
| US7498409B2 (en) | 2005-03-24 | 2009-03-03 | Schering Corporation | Screening assay for TLR7, TLR8 and TLR9 agonists and antagonists |
| MX2007013780A (es) | 2005-05-04 | 2008-02-05 | Pfizer Ltd | Derivados 2 amido-6-amino-8-oxo purina como moduladores del receptor como tipo peaje (toll) para el tratamiento del cancer y las infecciones virales tal como la hepatitis c. |
| US8227601B2 (en) | 2005-05-05 | 2012-07-24 | Ardea Biosciences, Inc. | Diaryl-purines, azapurines and -deazapurines as non-nucleoside reverse transcriptase inhibitor for treatment of HIV |
| AR054122A1 (es) | 2005-05-12 | 2007-06-06 | Tibotec Pharm Ltd | Pirido[2,3-d]pirimidas utiles como inhibidores de hcv, y metodos para la preparacion de las mismas |
| US7994360B2 (en) | 2005-05-16 | 2011-08-09 | Xtl Biopharmaceuticals Ltd. | Benzofuran compounds |
| TWI404537B (zh) | 2005-08-19 | 2013-08-11 | Array Biopharma Inc | 作為類鐸受體（ｔｏｌｌ-ｌｉｋｅ ｒｅｃｅｐｔｏｒ）調節劑之８-經取代苯并氮雜呯 |
| ES2612890T3 (es) | 2005-09-01 | 2017-05-19 | F. Hoffmann-La Roche Ag | Diaminopirimidinas como moduladores de P2X3 y P2X2/3 |
| EP1939198A4 (fr) | 2005-09-22 | 2012-02-15 | Dainippon Sumitomo Pharma Co | Nouveau compose d'adenine |
| WO2007056208A2 (fr) | 2005-11-02 | 2007-05-18 | Cytovia, Inc. | N-arylalkyl-thienopyrimidin-4-amines et analogues en tant qu'activateurs de caspases et inducteurs d'apoptose et utilisation de ceux-ci |
| US20090182140A1 (en) | 2005-12-02 | 2009-07-16 | Mitsubishi Tanabe Pharma Corporation | Alicyclic Heterocyclic Compound |
| JP2009528989A (ja) | 2006-02-17 | 2009-08-13 | ファイザー・リミテッド | Ｔｌｒ７変調剤としての３−デアザプリン誘導体 |
| US8673929B2 (en) | 2006-07-20 | 2014-03-18 | Gilead Sciences, Inc. | 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives and pharmaceutical compositions useful for treating viral infections |
| WO2008009078A2 (fr) | 2006-07-20 | 2008-01-24 | Gilead Sciences, Inc. | Dérivés de la quinazoline tri-substitués en 4,6-dl et en 2,4,6 utilisables pour traiter les infections virales |
| JP5500990B2 (ja) | 2006-12-07 | 2014-05-21 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | ホスホイノシチド３−キナーゼ阻害剤化合物及び使用方法 |
| CA2672250C (fr) | 2006-12-20 | 2013-04-30 | Ian Stansfield | Indoles antiviraux |
| ES2456964T3 (es) | 2007-02-07 | 2014-04-24 | The Regents Of The University Of California | Conjugados de agonistas de TLR sintéticos y usos de los mismos |
| JP2008222557A (ja) | 2007-03-08 | 2008-09-25 | Kotobuki Seiyaku Kk | ピロロ［３，２−ｄ］ピリミジン誘導体及びこれを有効成分とする医薬組成物 |
| SI2132209T1 (sl) | 2007-03-19 | 2014-05-30 | Astrazeneca Ab | Spojine 9-substituiranega-8-okso-adenina, kot modulatorji Toll-like receptorja (TLR7) |
| EP2138497A4 (fr) | 2007-03-20 | 2012-01-04 | Dainippon Sumitomo Pharma Co | Nouveau composé d'adénine |
| AR065784A1 (es) | 2007-03-20 | 2009-07-01 | Dainippon Sumitomo Pharma Co | Derivados de 8-oxo adenina,medicamentos que los contienen y usos como agentes terapeuticos para enfermedades alergicas, antivirales o antibacterianas. |
| CA2687821C (fr) | 2007-05-22 | 2015-04-14 | Boehringer Ingelheim International Gmbh | Inhibiteurs de benzimidazolone chymase |
| SI2170888T1 (sl) | 2007-06-29 | 2015-10-30 | Gilead Sciences, Inc. | Purinski derivati in njihova uporaba kot modulatorjev receptorja tipa toll-7 |
| US20120121540A1 (en) | 2007-08-10 | 2012-05-17 | Franz Ulrich Schmitz | Certain Nitrogen Containing Bicyclic Chemical Entities For Treating Viral Infections |
| WO2009032668A2 (fr) | 2007-08-28 | 2009-03-12 | Irm Llc | Composés et compositions en tant qu'inhibiteurs de kinase |
| WO2009030998A1 (fr) | 2007-09-05 | 2009-03-12 | Coley Pharmaceutical Group, Inc. | Composés pyrimidine utilisés comme agonistes du récepteur de type toll (tlr) |
| PE20091236A1 (es) | 2007-11-22 | 2009-09-16 | Astrazeneca Ab | Derivados de pirimidina como immunomoduladores de tlr7 |
| US8524716B2 (en) | 2007-12-24 | 2013-09-03 | Janssen R&D Ireland | Macrocyclic indoles as hepatitis C virus inhibitors |
| JP2011511073A (ja) | 2008-02-07 | 2011-04-07 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | Ｔｌｒ７活性化物質による膀胱の疾患の治療 |
| EP2271345B1 (fr) | 2008-04-28 | 2015-05-20 | Merck Sharp & Dohme Corp. | Inhibiteurs de la protéase hcv ns3 |
| US8946239B2 (en) | 2008-07-10 | 2015-02-03 | Duquesne University Of The Holy Spirit | Substituted pyrrolo, -furano, and cyclopentylpyrimidines having antimitotic and/or antitumor activity and methods of use thereof |
| UY31982A (es) | 2008-07-16 | 2010-02-26 | Boehringer Ingelheim Int | Derivados de 1,2-dihidropiridin-3-carboxamidas n-sustituidas |
| JP5600104B2 (ja) | 2008-08-01 | 2014-10-01 | ベンティアールエックス ファーマシューティカルズ， インコーポレイテッド | Ｔｏｌｌ様受容体アゴニスト処方物およびその使用 |
| BRPI1010937A2 (pt) | 2009-05-21 | 2019-09-24 | Astrazeneca Ab | composto, uso de um composto, e, método para tratar câncer |
| TWI468402B (zh) | 2009-07-31 | 2015-01-11 | 必治妥美雅史谷比公司 | 降低β－類澱粉生成之化合物 |
| US8637525B2 (en) | 2009-07-31 | 2014-01-28 | Bristol-Myers Squibb Company | Compounds for the reduction of beta-amyloid production |
| US20120232062A1 (en) | 2009-10-20 | 2012-09-13 | Eiger Biopharmaceuticals, Inc. | Azaindazoles to treat flaviviridae virus infection |
| MX2012004706A (es) | 2009-10-22 | 2012-06-08 | Gilead Sciences Inc | Derivados de purina o deazapurina utiles para el tratamiento de (inter alia) infecciones virales. |
| KR101094446B1 (ko) | 2009-11-19 | 2011-12-15 | 한국과학기술연구원 | 단백질 키나아제 저해활성을 가지는 2,4,7-치환된 티에노［3,2-ｄ］피리미딘 화합물 |
| JP2013032290A (ja) | 2009-11-20 | 2013-02-14 | Dainippon Sumitomo Pharma Co Ltd | 新規縮合ピリミジン誘導体 |
| DE102010040233A1 (de) | 2010-09-03 | 2012-03-08 | Bayer Schering Pharma Aktiengesellschaft | Bicyclische Aza-Heterocyclen und ihre Verwendung |
| RU2016118628A (ru) | 2010-10-01 | 2018-11-02 | Вентиркс Фармасьютикалз, Инк. | Способы лечения аллергических заболеваний |
| WO2012067269A1 (fr) | 2010-11-19 | 2012-05-24 | Dainippon Sumitomo Pharma Co., Ltd. | Composés aminoalcoxyphényle et leur utilisation dans le traitement de maladies |
| WO2012066335A1 (fr) | 2010-11-19 | 2012-05-24 | Astrazeneca Ab | Composés phénol en tant qu'agonistes du récepteur 7 de type toll |
| KR101946499B1 (ko) | 2011-04-08 | 2019-02-11 | 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 | 바이러스 감염 치료를 위한 피리미딘 유도체 |
| SG194852A1 (en) * | 2011-05-18 | 2013-12-30 | Janssen R & D Ireland | Quinazoline derivatives for the treatment of viral infections and further diseases |
| UA116083C2 (uk) | 2011-11-09 | 2018-02-12 | ЯНССЕН САЙЄНСІЗ АЙРЛЕНД ЮСі | Похідні пурину для лікування вірусних інфекцій |
| JP6283320B2 (ja) | 2012-02-08 | 2018-02-21 | ヤンセン・サイエンシズ・アイルランド・ユーシー | ウイルス感染の治療のためのピペリジノ−ピリミジン誘導体 |
| SI3459942T1 (sl) | 2012-04-24 | 2021-05-31 | Vertex Pharmaceuticals Incorporated | Inhibitorji DNA-PK |
| PT2872515T (pt) | 2012-07-13 | 2016-07-27 | Janssen Sciences Ireland Uc | Purinas macrocíclicas para o tratamento de infeções virais |
| MX369417B (es) | 2012-08-10 | 2019-11-07 | Janssen Sciences Ireland Uc | Derivados de alquilpirimidina para el tratamiento de infecciones víricas y otras enfermedades. |
| UY34993A (es) | 2012-08-28 | 2014-02-28 | Janssen R & D Ireland | Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b |
| EP2712866A1 (fr) | 2012-10-01 | 2014-04-02 | Centre National de la Recherche Scientifique (CNRS) | Dérivés de 1,2,4-triazine pour le traitement d'infections virales |
| SG11201502589YA (en) | 2012-10-05 | 2015-04-29 | Janssen Sciences Ireland Uc | Acylaminopyrimidine derivatives for the treatment of viral infections and further diseases |
| EA035327B1 (ru) | 2012-10-10 | 2020-05-28 | Янссен Сайенсиз Айрлэнд Юси | Производные пирроло[3,2-d]пиримидина для лечения вирусных инфекций и других заболеваний |
| ES2655843T3 (es) | 2012-11-16 | 2018-02-21 | Janssen Sciences Ireland Uc | Derivados 2-aminoquinazolínicos sustituidos heterocíclicos para el tratamiento de infecciones víricas |
| MY191389A (en) | 2013-02-21 | 2022-06-22 | Janssen Sciences Ireland Uc | 2-aminopyrimidine derivatives for the treatment of viral infections |
| CN105338983B (zh) | 2013-03-29 | 2019-10-25 | 爱尔兰詹森科学公司 | 用于治疗病毒感染的大环脱氮-嘌呤酮 |
| JO3583B1 (ar) | 2013-05-17 | 2020-07-05 | Janssen Sciences Ireland Uc | مشتقات سلفامويل بيرولاميد واستخدامها كادوية لمعالجة التهاب الكبد نوع بي |
| JP6377139B2 (ja) | 2013-05-24 | 2018-08-22 | ヤンセン・サイエンシズ・アイルランド・ユーシー | ウイルス感染症およびさらなる疾患の処置のためのピリドン誘導体 |
| JP6763769B2 (ja) | 2013-06-27 | 2020-09-30 | ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー | ウイルス感染症および他の疾病の処置のためのピロロ［３，２−ｄ］ピリミジン誘導体 |
| MX368625B (es) * | 2013-07-30 | 2019-10-08 | Janssen Sciences Ireland Uc | Derivados de tieno[3,2-d]pirimidinas para el tratamiento de infecciones virales. |
| EP3166938A4 (fr) | 2014-07-11 | 2018-01-17 | Northwestern University | Échafaudages 2-imidazolyl-pyrimidine en tant qu'inhibiteurs puissants et sélectifs de l'oxyde nitrique synthase neuronale |
| DK3097102T3 (en) * | 2015-03-04 | 2018-01-22 | Gilead Sciences Inc | TOLL-LIKE RECEPTOR MODULATING 4,6-DIAMINO-PYRIDO [3,2-D] PYRIMIDINE COMPOUNDS |
| AR107633A1 (es) | 2016-02-19 | 2018-05-16 | Hoffmann La Roche | Procedimiento para la preparación del ácido 4-fenil-5-alcoxicarbonil-2-tiazol-2-il-1,4-dihidropirimidin-6-il-[metil]-3-oxo-5,6,8,8a-tetrahidro-1h-imidazo[1,5a]pirazin-2-il-carboxílico |
| KR20180129943A (ko) | 2016-04-15 | 2018-12-05 | 노비라 테라퓨틱스, 인코포레이티드 | 캡시드 조립 억제제를 포함하는 배합물 및 방법 |
| SG11201811448RA (en) * | 2016-07-01 | 2019-01-30 | Janssen Sciences Ireland Unlimited Co | Dihydropyranopyrimidines for the treatment of viral infections |
| MA46093A (fr) * | 2016-09-02 | 2021-05-19 | Gilead Sciences Inc | Composés modulateurs du recepteur de type toll |
| TW202415645A (zh) * | 2018-03-01 | 2024-04-16 | 愛爾蘭商健生科學愛爾蘭無限公司 | ２，４－二胺基喹唑啉衍生物及其醫學用途 |
-
2019
- 2019-02-26 TW TW112147878A patent/TW202415645A/zh unknown
- 2019-02-26 TW TW108106429A patent/TW201945003A/zh unknown
- 2019-02-28 BR BR112020017702-4A patent/BR112020017702A2/pt not_active IP Right Cessation
- 2019-02-28 IL IL276952A patent/IL276952B2/en unknown
- 2019-02-28 JP JP2020544896A patent/JP2021514981A/ja not_active Ceased
- 2019-02-28 LT LTEPPCT/EP2019/054941T patent/LT3759083T/lt unknown
- 2019-02-28 DK DK19708817.2T patent/DK3759083T3/da active
- 2019-02-28 CA CA3091076A patent/CA3091076A1/fr active Pending
- 2019-02-28 SI SI201930268T patent/SI3759083T1/sl unknown
- 2019-02-28 HR HRP20220781TT patent/HRP20220781T1/hr unknown
- 2019-02-28 PL PL19708817.2T patent/PL3759083T3/pl unknown
- 2019-02-28 MD MDE20210025T patent/MD3759083T2/ro unknown
- 2019-02-28 WO PCT/EP2019/054941 patent/WO2019166532A1/fr not_active Ceased
- 2019-02-28 MA MA52411A patent/MA52411B1/fr unknown
- 2019-02-28 ES ES19708817T patent/ES2923579T3/es active Active
- 2019-02-28 UA UAA202006229A patent/UA127590C2/uk unknown
- 2019-02-28 EA EA202092052A patent/EA202092052A1/ru unknown
- 2019-02-28 SM SM20220315T patent/SMT202200315T1/it unknown
- 2019-02-28 HU HUE19708817A patent/HUE059149T2/hu unknown
- 2019-02-28 CN CN201980016340.4A patent/CN111868040A/zh active Pending
- 2019-02-28 PT PT197088172T patent/PT3759083T/pt unknown
- 2019-02-28 EP EP22170830.8A patent/EP4059924A1/fr not_active Withdrawn
- 2019-02-28 US US16/977,043 patent/US11597704B2/en active Active
- 2019-02-28 RS RS20220684A patent/RS63401B1/sr unknown
- 2019-02-28 KR KR1020207024889A patent/KR20200128394A/ko not_active Withdrawn
- 2019-02-28 IL IL305388A patent/IL305388A/en unknown
- 2019-02-28 EP EP19708817.2A patent/EP3759083B1/fr active Active
- 2019-02-28 AU AU2019226342A patent/AU2019226342B2/en not_active Expired - Fee Related
- 2019-02-28 AR ARP190100506A patent/AR114420A1/es not_active Application Discontinuation
- 2019-02-28 SG SG11202008293YA patent/SG11202008293YA/en unknown
- 2019-02-28 MX MX2020009071A patent/MX2020009071A/es unknown
-
2020
- 2020-08-27 PH PH12020551345A patent/PH12020551345A1/en unknown
- 2020-08-30 JO JOJO/P/2020/0208A patent/JOP20200208B1/ar active
- 2020-08-31 MX MX2023001803A patent/MX2023001803A/es unknown
- 2020-08-31 CL CL2020002253A patent/CL2020002253A1/es unknown
-
2021
- 2021-06-30 CL CL2021001753A patent/CL2021001753A1/es unknown
-
2022
- 2022-01-18 CL CL2022000125A patent/CL2022000125A1/es unknown
- 2022-07-27 CY CY20221100514T patent/CY1125489T1/el unknown
-
2023
- 2023-01-24 US US18/159,026 patent/US20230278964A1/en not_active Abandoned
- 2023-09-05 JO JOJO/P/2023/0207A patent/JOP20230207A1/ar unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JOP20200208A1 (ar) | مشتقات 2، 4-داي أمينو كوينازولين والاستخدامات الطبية لها | |
| RU2378263C2 (ru) | Производные 5-фенилтиазола и их применение в качестве ингибиторов рi3 киназы | |
| MA58170B1 (fr) | Dérivés carboxy avec des proprietes anti-inflammatoires | |
| MA44021B1 (fr) | Composés antitumoraux | |
| MA27764A1 (fr) | Acides carboxyliques alpha-substitués servant de modulateurs de PPAR | |
| JP2019512485A5 (fr) | ||
| ME00376B (me) | DIHIDROPTERIDINONI, POSTUPAK ZA NJlHOVO PRIPREMANJE I NJlHOVA PRIMJENA KAO LIJEK | |
| MA50069B1 (fr) | Dérivés 1-(4-(isoxazol-5-yl)-1h-pyrazol-1-yl)-2-méthylpropan-2-ol et composés similaires en tant qu'inhibiterus il-7 et ifn-gamma pour le traitement de maladies autoimmune et inflammation chronique | |
| MA43639B1 (fr) | Nouveaux dérivés d'ammonium, procédé de préparation de ceux-ci et compositions pharmaceutiques les contenant | |
| ATE463483T1 (de) | 6-substituierte isochinolinderivate als rock-1- inhibitoren | |
| HRP20211102T1 (hr) | Supstituirani derivati indolina kao inhibitori replikacije denga virusa | |
| MX2023011864A (es) | Inhibidores de dihidroorotato deshidrogenasa deuterados. | |
| MA31674B1 (fr) | Dérivés de 7 -alkynyl-1,8-naphthyridones, leur préparation et leur application en thérapeutique | |
| MA41885B1 (fr) | Mélange d'additifs | |
| FR3037953B1 (fr) | Procede de synthese de molecules portant une fonction oxyde de nitrile | |
| CA2531484A1 (fr) | Nouveaux bioisosteres d'actinonine | |
| ZA202405279B (en) | Heteroaryl derivative and use thereof | |
| MA56324B1 (fr) | Inhibiteurs de l'arginase et leurs procédés d'utilisation | |
| PE20242348A1 (es) | Agentes antivirales para el tratamiento y la prevencion de la infeccion por vih | |
| EA202290157A1 (ru) | Производные третичных аминов и их применение для лечения вирусной инфекции | |
| FR3058640B1 (fr) | Composes pour leur utilisation dans le traitement de la grippe | |
| FR3092114B1 (fr) | Nouveaux derives de purine et medicaments les comprenant | |
| MA57420B1 (fr) | Composés anticancéreux | |
| PE20251286A1 (es) | Inhibidores del virus respiratorio sincitial humano y del metapneumovirus | |
| NZ807753A (en) | 2,4-diaminoquinazoline derivatives and medical uses thereof |